WallStreetZenWallStreetZen

NASDAQ: HCAT
Health Catalyst Inc Stock Forecast, Predictions & Price Target

Buy HCAT

Analyst price target for HCAT

Based on 10 analysts offering 12 month price targets for Health Catalyst Inc.
Min Forecast
$16.00+36.87%
Avg Forecast
$25.20+115.57%
Max Forecast
$50.00+327.72%

Should I buy or sell HCAT stock?

Based on 11 analysts offering ratings for Health Catalyst Inc.
Strong Buy
Strong Buy
7 analysts 63.64%
Buy
2 analysts 18.18%
Hold
2 analysts 18.18%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

HCAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Raymond James
Top 18%
83
Strong BuyMaintains$20.00+71.09%2022-08-09
Stifel Nicolaus
Top 4%
97
HoldDowngrades$16.00+36.87%2022-08-05
JP Morgan
Top 39%
62
HoldDowngrades$16.00+36.87%2022-08-05
Anonymous
Goldman Sachs
Strong BuyMaintains$37.00+216.51%2022-05-26
Citigroup
Top 13%
88
Strong BuyMaintains$25.00+113.86%2022-05-11
RBC Capital
Top 23%
78
BuyMaintains$19.00+62.53%2022-05-11
Piper Sandler
Bottom 25%
25
Strong BuyMaintains$21.00+79.64%2022-05-11
SVB Leerink
Bottom 2%
2
BuyMaintains$22.00+88.20%2022-05-11
BTIG
Bottom 8%
8
Strong BuyMaintains$50.00+327.72%2022-03-25
Jefferies
Top 22%
79
Strong BuyUpgrades$28.00+139.52%2022-03-17

1 of 2

Forecast return on equity

Is HCAT forecast to generate an efficient return?
Company
N/A
Industry
10%
Market
56.05%

Forecast return on assets

Is HCAT forecast to generate an efficient return on assets?
Company
N/A
Industry
6.61%

HCAT earnings per share forecast

What is HCAT's earnings per share in the next 2 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$1.83
Avg 2 year Forecast
-$1.70

HCAT revenue forecast

What is HCAT's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$281.0M+5.96%
Avg 2 year Forecast
$328.2M+23.75%
Avg 3 year Forecast
$383.2M+44.52%
HCAT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HCAT revenue growth forecast

How is HCAT forecast to perform vs Health Information Services companies and vs the US market?
Company
11.66%
Industry
15.89%
Market
8.19%
HCAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HCAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HCAT vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
HCAT$11.69$25.20+115.57%Strong Buy
HLTH$4.34$14.67+237.95%Buy
SMFR$1.84$10.50+470.65%Strong Buy
CMAX$7.95$14.50+82.39%Strong Buy
HSTM$23.63$24.00+1.57%Buy

Health Catalyst Stock Forecast FAQ

Is Health Catalyst Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NASDAQ: HCAT) stock is to Strong Buy HCAT stock.

Out of 11 analysts, 7 (63.64%) are recommending HCAT as a Strong Buy, 2 (18.18%) are recommending HCAT as a Buy, 2 (18.18%) are recommending HCAT as a Hold, 0 (0%) are recommending HCAT as a Sell, and 0 (0%) are recommending HCAT as a Strong Sell.

If you're new to stock investing, here's how to buy Health Catalyst stock.

What is HCAT's earnings growth forecast for 2022-2023?

(NASDAQ: HCAT) Health Catalyst's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 12.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.92%.

Health Catalyst's earnings in 2022 is -$144,892,000.On average, 6 Wall Street analysts forecast HCAT's earnings for 2022 to be -$100,143,778, with the lowest HCAT earnings forecast at -$124,769,297, and the highest HCAT earnings forecast at -$79,896,129.

In 2023, HCAT is forecast to generate -$93,029,739 in earnings, with the lowest earnings forecast at -$135,166,739 and the highest earnings forecast at -$68,404,220.

What is HCAT's revenue growth forecast for 2022-2024?

(NASDAQ: HCAT) Health Catalyst's forecast annual revenue growth rate of 11.66% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 15.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.19%.

Health Catalyst's revenue in 2022 is $265,173,000.On average, 7 Wall Street analysts forecast HCAT's revenue for 2022 to be $15,376,611,975, with the lowest HCAT revenue forecast at $14,940,028,882, and the highest HCAT revenue forecast at $15,924,283,522. On average, 7 Wall Street analysts forecast HCAT's revenue for 2023 to be $17,958,077,792, with the lowest HCAT revenue forecast at $15,876,893,079, and the highest HCAT revenue forecast at $19,179,996,054.

In 2024, HCAT is forecast to generate $20,971,475,214 in revenue, with the lowest revenue forecast at $18,258,454,402 and the highest revenue forecast at $23,070,226,131.

What is HCAT's forecast return on assets (ROA) for 2022-2024?

(NASDAQ: HCAT) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of 6.61%.

What is HCAT's Price Target?

According to 10 Wall Street analysts that have issued a 1 year HCAT price target, the average HCAT price target is $25.20, with the highest HCAT stock price forecast at $50.00 and the lowest HCAT stock price forecast at $16.00.

On average, Wall Street analysts predict that Health Catalyst's share price could reach $25.20 by Aug 9, 2023. The average Health Catalyst stock price prediction forecasts a potential upside of 115.57% from the current HCAT share price of $11.69.

What is HCAT's Earnings Per Share (EPS) forecast for 2022-2023?

(NASDAQ: HCAT) Health Catalyst's current Earnings Per Share (EPS) is -$2.82. On average, analysts forecast that HCAT's EPS will be -$1.83 for 2022, with the lowest EPS forecast at -$2.28, and the highest EPS forecast at -$1.46. In 2023, HCAT's EPS is forecast to hit -$1.70 (min: -$2.47, max: -$1.25).

What is HCAT's forecast return on equity (ROE) for 2022-2024?

(NASDAQ: HCAT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.